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High Prevalence of Low Bone Mineral Density
and Substantial Bone Loss over 4 Years
Among HIV-Infected Persons in the Era
of Modern Antiretroviral Therapy
Gerome V. Escota,1 Kristin Mondy,2 Tim Bush,3 Lois Conley,3 John T. Brooks,3 Nur Önen,1
Pragna Patel,4 Erna Milunka Kojic,5 Keith Henry,6 John Hammer,7 K.C. Wood,8
Kenneth A. Lichtenstein,9 and Edgar T. Overton,10 for the SUN Study Investigators

Abstract

HIV-infected persons are living longer on combination antiretroviral therapy (cART) but experiencing more
comorbidities including low bone mineral density (BMD). Using data from the Study to Understand the Natural
History of HIV and AIDS in the Era of Effective Therapy (SUN Study), we determined the prevalence of low
BMD (T-score below one standard deviation of the reference mean) and compared it with matched controls
from the National Health and Nutrition Examination Survey (NHANES). We also assessed 4-year longitudinal
BMD changes among participants virologically suppressed on cART. Of 653 participants included in this analysis
(77% male, 29% black, median age 41 years, median CD4+ cell count 464 cells/mm3, 89% with HIV RNA <400
copies/ml), 51% and 10% had baseline osteopenia and osteoporosis, respectively. Low BMD at the femoral neck
was significantly more prevalent than for the NHANES controls (47% versus 29%, p < 0.001). Lower body mass
index, nonwhite race, longer tenofovir exposure, older age, being unemployed or retired, and lower apolipoprotein
E were independently associated with baseline osteoporosis. Among 170 participants virologically suppressed on
cART and with longitudinal BMD data, 31% experienced substantial bone loss (‡5% BMD decline from
baseline) over 4 years. Female sex, current smoking, and longer stavudine use were more common among
participants who had substantial bone loss, although these variables failed to reach statistical significance. Low
BMD was highly prevalent among HIV-infected persons. One-third of participants experienced substantial bone
loss despite cART, suggesting the need for monitoring and potential clinical interventions.

the prevalence of osteoporosis, longitudinal evaluations of
changes in bone mineral density (BMD) over time among
HIV-infected persons are limited.
Osteopenia and osteoporosis remain highly prevalent
among HIV-infected persons, ranging from 40% to 62% and
14% to 42%, respectively.4–6 Studies that assessed the progression of BMD among HIV-infected persons have yielded
inconsistent results. Some studies demonstrated accelerated

Introduction

W

ith the advent of combination antiretroviral
therapy (cART), survival has improved among HIVinfected persons with a marked reduction in AIDS-associated
complications.1 However, age-related comorbidities including osteoporosis occur with higher frequency as compared to
the general population.2,3 While there are substantial data on
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bone loss, while others showed stable or even increased BMD
over time.7–9 A meta-analysis reported that in studies that
involved treatment-naive or untreated persons at baseline,
BMD significantly declined at 1, 2, and 2.5 years after cART
initiation. Conversely, in cohorts that involved cART-treated
persons at baseline, BMD was stable over time.10 One study
documented a 2–6% decline in BMD within the first 2 years
of cART initiation independent of antiretroviral regimen.11
In the setting of long-term viral suppression, understanding the complications of HIV infection and cART is paramount to successful HIV management. In the current
analysis, we evaluated baseline BMD in a contemporary
cohort of HIV-infected individuals to determine the prevalence of osteopenia and osteoporosis and then compared the
findings to those from persons matched by age, sex, race, and
body mass index (BMI) from the National Health and Nutrition Examination Survey (NHANES). We then assessed
longitudinal BMD changes to determine the proportion of
persons virologically suppressed on cART with progressive
BMD decline over 4 years, and identified associated risk
factors.
Materials and Methods
Study to Understand the Natural History of HIV
and AIDS in the Era of Effective Therapy (SUN Study)

This was a prospective, observational cohort funded by the
Centers for Disease Control and Prevention (CDC) that
monitored the clinical course of HIV-infected persons treated
with cART at seven HIV specialty clinics in four cities in the
United States: St. Louis, Missouri; Providence, Rhode Island;
Minneapolis, Minnesota; and Denver, Colorado. Seven
hundred HIV-infected persons were enrolled between March
2004 and June 2006 and were followed until June 2012. Informed consent was obtained from all study participants, and
the study was approved and renewed annually by the institutional review boards of all participating institutions and the
CDC. The cohort and detailed study methodology have been
described elsewhere.12
Briefly, at baseline, comprehensive clinical and behavioral
data were collected on all subjects including height and
weight for calculating BMI, type and duration of all medications, behavioral risk data including alcohol, tobacco use,
and substance abuse, comorbidities, and fasting laboratory
data. Laboratory tests used for research only including insulin, adiponectin, leptin, highly-sensitive C-reactive protein,
and 25-hydroxyvitamin D were performed by the Diabetes
Research and Training Center Radioimmunoassay Core Laboratory, Washington University School of Medicine. Serum
and plasma used for these tests were placed on ice immediately, centrifuged, and stored at -70C until time of batched
assay. At enrollment and annually for the following 4 years,
whole-body and site-specific dual X-ray absorptiometry
(DXA) scans, performed on Lunar or Hologic machines,
were obtained by each study site on all participants and
transmitted to central readers for interpretation.
National Health and Nutrition Examination
Survey (NHANES)

The NHANES has been conducted annually by the National Center for Health Statistics since 1999.13 Each year,
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NHANES surveys a nationally representative sample of approximately 5,000 persons from 15 counties across the United States. Each person is interviewed to collect demographic
and socioeconomic data and examined to obtain medical and
laboratory measures, including use of DXA scans on Hologic
machines to evaluate femoral neck BMD. NHANES data are
released in 2-year cycles and we used the 2007–2008 cycle to
compare to our data, matching 1:1 based on age, sex, race,
and BMI. Because NHANES releases only T-score data, this
analysis was conducted using this measure.
Definitions

We used the World Health Organization (WHO) classification of BMD utilizing the difference between an individual’s BMD and that of a young-adult reference population
(T-score). In postmenopausal women and men at least 50
years, a T-score that is within one standard deviation (SD) of
the reference BMD is classified as normal, 1 to 2.5 SD below
the reference BMD as osteopenia, and greater than 2.5 SD
below the reference BMD as osteoporosis.14 The classification of low BMD includes all persons with either osteopenia or osteoporosis. We defined substantial BMD decline
as ‡5% decrease from baseline at year 1 to 4 of follow-up at
the femoral neck, total hip, or lumbar spine. Participants
with <5% decrease or any percent increase in baseline BMD
at years 1 to 4 were categorized as having stable and increased BMD, respectively. For the longitudinal analysis,
we defined virologic suppression as HIV RNA below the
limit of detection at all time points. Blips (i.e., HIV RNA
between the limit of detection and <2,000 copies/ml that
were followed by HIV RNA below the limit of detection on
subsequent testing) were categorized as viral suppression.
On the other hand, virologic nonsuppression was defined as
any HIV RNA ‡2,000.
Statistical analysis

For univariate analysis, statistical associations between
each outcome and categorical variables were tested using the
chi-square test or Fisher’s exact test. Associations with
continuous variables were analyzed by either the Student’s ttest or Wilcoxon rank-sum test for normally and nonnormally
distributed variables, respectively. All tests of statistical
significance were two-sided. Variables that were associated
with osteoporosis versus no osteoporosis at any site, as indicated by p < 0.10 in univariate analysis, were then modeled
using stepwise logistic regression.15 Continuous variables
were converted to quartile groups to facilitate interpretation
of odds ratios. We determined the prevalence of low BMD
and compared it with controls matched by age, sex, race, and
BMI from NHANES using the paired t-test.
For assessment of longitudinal BMD change, we included
participants who were virologically suppressed while taking
cART for at least 2 years prior to baseline and had BMD data
for 4 consecutive years during study follow-up. Baseline
demographic and laboratory data were used as variables to
determine significant associations with BMD loss from
baseline. We used the chi-square test, the Student’s t-test, and
the Wilcoxon rank-sum test to compare differences between
participants who did and did not have substantial BMD decline. All statistical analyses were performed using SAS,
version 9.3 (SAS Institute, Inc., Cary, NC).16

LOW BMD AND PROGRESSIVE BONE LOSS
Results
Baseline BMD

A total of 653 SUN Study participants had DXA and
clinical data available for analysis. Twenty-nine percent were
African American, 10% were Hispanic, and 23% were female, and the median age was 41 years. The median CD4+
cell count was 464 cells/mm3 with 523 (79%) persons currently on cART, among whom 89% had HIV RNA <400
copies/ml. At the lumbar spine, 46% had low BMD (38%
with osteopenia and 8% with osteoporosis). At the femoral
neck, 46% had low BMD (42% with osteopenia and 4% with
osteoporosis). At the total hip, 28% had low BMD (26% with
osteopenia and 2% with osteoporosis). At any site, 61% had
evidence of low BMD (51% with osteopenia and 10% with
osteoporosis). Additional characteristics of the study subjects
are shown in Table 1.
In multivariate logistic regression, the following factors were
independently associated with osteoporosis: age >46 years
[odds ratio (OR) 2.27; 95% confidence interval (CI) 1.26–4.07;
p = 0.006]; nonwhite race (OR 2.58; 95% CI 1.45–4.65;
p = 0.001); BMI <22.8 kg/m2 (OR 3.96; 95% CI 2.23–7.07;
p =<0.001); being unemployed or retired (OR 2.16; 95% CI
1.16–3.94; p = 0.013); time on tenofovir >1 year (OR 2.47; 95%
CI 1.35–4.48; p = 0.003); and apolipoprotein E <4.8 mg/liter
(OR 1.97; 95% CI 1.10–3.59; p = 0.023) (Table 2). Of note,
markers of bone turnover [i.e., cross-linked C-telopeptide of
type 1 collagen (CTx), osteocalcin, alkaline phosphatase) were
significantly elevated among participants with low BMD but
were not independently associated with osteoporosis by multivariate analysis. Furthermore, persons with low BMD had a
median 25-hydroxyvitamin D that did not statistically differ
from those with normal BMD.
Comparison with NHANES subjects

Femoral neck BMD measurements of the 462 SUN participants whose DXA scan was performed on a Hologic
scanner were compared to data from NHANES to determine
relative rates of osteopenia and osteoporosis. The mean
T-score at the femoral neck was -0.81 for the SUN cohort
versus -0.33 for the NHANES group ( p < 0.001) (Fig. 1).
Low BMD at the femoral neck was significantly more
prevalent in the SUN group than the NHANES group (47%
versus 29%) ( p < 0. 001), with osteopenia found in 45%
versus 28% ( p < 0.001) and osteoporosis found in 3.5%
versus 0.9% ( p = 0.005).
Longitudinal BMD change

There were 170 SUN Study participants who were virologically suppressed at baseline with at least 2 years of cART
and with 4-year longitudinal BMD data available. Over this
4-year period, BMD was stable in 35% of participants at the
femoral neck, 49% at the total hip, and 29% at the lumbar
spine; BMD increased in 50% at the femoral neck, 35% at the
total hip, and 54% at the lumbar spine. The proportion of
participants who had ‡5% decline in BMD from baseline
increased over time such that at year 4, 15% had substantial
bone loss at the femoral neck, 15% at the total hip, 17% at the
lumbar spine, and 31% at any site (Fig. 2). In univariate
analysis, certain parameters were more common in those with
substantial bone loss including female sex, current smoking,
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and longer stavudine use; however, these failed to reach
statistical significance (Supplementary Table S1; Supplementary Data are available online at www.liebertpub.com/
aid). The BMI of participants who had substantial bone loss at
any site also did not significantly change over 4 years. The
majority of subjects remained in the same WHO BMD
classification at 4 years and the prevalence of WHO-defined
osteopenia or osteoporosis also remained stable over time.
We found a modest negative correlation between lower BMD
at baseline and increased BMD over time at the total hip
(r = - 0.19, p = 0.015) but not at other sites.
Discussion

Consistent with several other studies, the prevalence of
osteopenia or osteoporosis was high (61%) in this cohort of
HIV-infected persons with mostly well-controlled viremia
and high CD4+ cell counts.4–6 In comparison to controls from
NHANES matched by age, sex, race, and BMI, our cohort had
significantly lower T-scores at the femoral neck with almost
twice as many persons with osteopenia and osteoporosis.
These findings confirm other data regarding the robust association of HIV infection with low BMD. Furthermore, a significant number of persons on cART continue to experience
bone loss despite suppressed viremia.
The mechanism of bone loss associated with HIV infection
is multifactorial. Previous studies have highlighted the high
prevalence of osteopenia and osteoporosis among cARTnaive persons and those with poorly controlled HIV infection
(low CD4+ cell count and detectable HIV-RNA), suggesting
direct (increased osteoclastic activity and decreased bone
formation caused by HIV-associated proteins) or indirect
(aberrant B cell activation with stimulation of osteoclast activity) viral effects in reducing BMD.5,17–19 Chronic immune
activation and inflammation, in turn, have been linked with
bone loss associated with HIV infection.20
In this analysis, we did not find an independent association
of osteoporosis with metabolic risk factors that have been
previously associated with osteoporosis in HIV-infected
persons (e.g., vitamin D deficiency).21 We also did not find an
independent association with markers of chronic inflammation, including high-sensitivity C-reactive protein (hs-CRP)
and bone turnover determined by cross-linked CTx and osteocalcin. However, we identified several traditional risk
factors associated with osteoporosis, including older age,
lower BMI, and in the HIV-infected population, longer use of
tenofovir. The association of tenofovir has been reported not
only among HIV-infected treatment-naive persons started on
tenofovir but also among HIV-uninfected persons receiving
tenofovir for preexposure prophylaxis.7,22 Longer cumulative exposure to tenofovir has also been independently associated with an increased risk of osteoporotic fracture.23
We also found novel associations of osteoporosis with
being unemployed or retired and with lower serum apolipoprotein E. To our knowledge, the independent association
with being unemployed or retired has not previously been
reported in the HIV literature, although, a link between the
level of education and low BMD has been seen in a cohort of
HIV-infected persons in Ireland.24 In the general population,
the association of unemployment with risk of osteoporotic
fracture has been described.25 Low socioeconomic status, as
evidenced by unemployment and low income, is strongly
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HIV-related factors
Time since HIV diagnosis in yearsa
History of opportunistic infectionc
Nadir CD4 count (cells/mm3)a
CD4 count (cells/mm3)a
ART naı̈vec
cART, current
Length of any ART (months) (IQR)a
On ARTc
HIV RNA <400 copies/ml

Characteristic
Age (years)a
Genderc
Men
Women
Race/ethnicityc
White, non-Hispanic
Black, non-Hispanic
Hispanic
Other/unknown
BMI (kg/m2)a
VAT (kg)a
SAT (kg)a
VAT/SATa
Any resistance training/exercisec
Any aerobics/exercisec
Employed full-timec
Tobacco smoking, ever
Tobacco smoking, current
History of substance abusec
Alcohol use in last 30 daysc
Postmenopausalc,d

177 (88)

455 (89)

145 (57)
83 (33)
21 (8)
5 (2)
26.9 (24.3–30.5)
117.8 (83.0–160.8)
231.6 (154.1–375.4)
0.51 (0.33–0.74)
108 (46)
107 (45)
127 (52)
164 (67)
111 (45)
172 (68)
171 (70)
10 (14)

386 (59)
188 (29)
64 (10)
15 (2)
25.5 (22.8–28.4)
115.6 (77.0–158.6)
192.4 (129.4–301.8)
0.57 (0.39–0.82)
248 (40)
296 (48)
302 (48)
426 (67)
280 (44)
451 (69)
444 (70)
22 (18)
4.5 (2.2–7.3)
57 (22)
205 (98–338)
470.5 (334.5–707.5)
28 (11)
203 (80)
29.7 (10.9–60.0)

169 (67)
85 (33)

505 (77)
148 (23)

4.8 (2.2–8.0)
155 (24)
204 (89–316)
464.5 (332–673)
76 (12)
515 (79)
32.6 (13.3–65.1)

40 (33–44)

Normal BMD (n = 254)

41 (35–47)

All participants (n = 653)

230 (89)

5.1 (2.2–8.1)
78 (23)
213.5 (92–309)
476 (328–651)
42 (12)
259 (77)
34.5 (14.0–70.7)

(continued)

48 (91)

6.6 (2.5–11.0)b
20 (32)
139.5 (34–269)b
413 (242–595)b
6 (10)
53 (84)
35.3 (18.0–72.6)

27 (43)
23 (37)
12 (19)
1 (2)
22.6 (20.7–25.1)b
100.8 (61.4–136.3)b
149.3a (100.1–227.1)
0.61 (0.47–0.98)b
19 (33)
20 (34)
17 (27)b
44 (71)
35 (56)
39 (62)
43 (69)
1 (20)

54 (86)b
9 (14)

282 (84)b
54 (16)
214 (64)
82 (24)
31 (9)
9 (3)
24.7 (22.6–27.4)b
118.1 (74.9–163.4)
179.5 (118.2–263.6)b
0.62a (0.43–0.88)b
121 (37)b
169 (52)
158 (48)
218 (66)
134 (40)
240 (71)
230 (69)
11 (25)

45 (38–51)b

Osteoporosis (n = 63)

42 (35.5–48)b

Osteopenia (n = 336)

Table 1. Baseline Characteristics of Participants by Bone Mineral Density Classification, the SUN Study, (n = 653), 2004–2012
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(56)
(55)
(88)
(26)
(45)
(39)

78 (13)
96.6 (83.0–110.6)
1.6 (1.1–2.3)
20.8 (13.5–89.1)
8.5 (5.3–13.6)
8,152.5 (5,225–12,410)
4.3 (2.2–9.2)
1.8 (0.8–4.5)
23.5 (15.5–31.4)
302 (190–438)
2.3 (1.4–3.5)
80.5 (66.0–101.5)
4.8 (3.9–5.8)

3.7 (0–24.9)
3.2 (0–26.4)
25.7 (7.5–59.0)

367
362
574
171
297
257

21 (9)
96.9 (83.1–110.7)
1.7 (1.2–2.4)
20.7 (13.9–93.7)
8.5 (5.8–13.8)
7,730 (4,980–10,720)
5.6 (2.6–13.6)
1.9 (0.8–5.0)
23.2 (15.4–31.3)
284 (172–406)
2.0 (1.1–2.6)
77.5 (64.5–98.0)
4.7 (3.8–5.8)

1.8 (0–20.7)
2.5 (0–22.7)
22.1 (5.8–55.2)

136 (54)
141 (56)
225 (89)
52 (20)
117 (46)
103 (41)

Normal BMD (n = 254)

42 (13)
95.3 (82.8–109.7)
1.6 (1.1–2.2)
21.1 (13.0–89.1)
8.7 (5.1–13.5)
8,162.5 (5,327.5–13,070)
3.7 (2.0–7.0)b
1.7 (0.7–4.2)
24.3 (16.1–31.9)
311 (214–441.5)b
2.7 (1.6–4.1)b
81 (67–100)
4.9 (4.0–5.8)

6.1 (0–27.9)
3.2 (0–27.2)
27.8 (7.9–64.8)

197 (59)
182 (54)
292 (87)
96 (29)b
146 (43)
122 (36)

Osteopenia (n = 336)

15 (26)b
97.9 (84.1–114.0)
1.5 (1.1–2.6)
20.7 (12.1–73.0)
8.1 (4.3–13.2)
9,815 (5,775–13,230)b
3.0 (1.6–6.1)b
1.6 (0.7–3.4)
21.5 (13.6–29.3)
355 (201–483)b
3.2 (2.0–5.8)
88 (77–115)b
5.7 (4.4–5.1)

2.5 (0–34.9)
9.4 (0–34.3)
33.5 (11.3–60.9)

34 (54)
39 (62)
57 (90)
23 (37)b
34 (54)
32 (51)

Osteoporosis (n = 63)

c

b

Median (IQR).
Denotes p value < 0.05; normal BMD versus osteopenia, normal BMD versus osteoporosis.
n (%).
d
Women only.
e
Men only.
SUN Study, Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy; BMD, bone mineral density; IQR, interquartile range; BMI, body mass index; VAT, visceral
adipose tissue; SAT, subcutaneous adipose tissue; ART, antiretroviral therapy; PI, protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase
inhibitor; eGFR, estimated glomerular filtration rate; sMDRD, simplified Modification of Diet in Renal Disease; TSH, thyroid-stimulating hormone; CTX, cross-linked C-telopeptide of type 1
collagen.

a

Laboratory parameters
Hepatitis C antibody-reactivec
eGFR by sMDRD (ml/min)a
TSH (mU/liter)a
Free testosterone (ng/dl)a,e
Fasting insulin (mU/liter)a
Adiponectin (lg/ml)a
Leptin (ng/ml)a
Highly sensitive C-reactive protein (mg/liter)a
25-hydroxyvitamin D (ng/ml)a
CTX (ng/ml)a
Osteocalcin (ng/ml)a
Alkaline phosphatase (IU/liter)a
Apolipoprotein E (mg/l)a

ART usec
Any use of PI
Any use of NNRTI
Any use of NRTI
Any use of stavudine
Any use of tenofovir
Current use tenofovir
Duration of ART use in monthsa
Any PI
Any NNRTI
Any NRTI

All participants (n = 653)

Table 1. (Continued)
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linked to poorer health outcomes, including increased allcause mortality.26 The association we found between nonwhite race and osteoporosis was not expected. It may have
been a result of unmeasured variables that influence outcome
that are different among racial groups (i.e., socioeconomic
factors such as annual income and geographic location, family
history of osteoporosis, use of calcium and other supplements).
The independent association of osteoporosis with lower
serum apolipoprotein E is intriguing. Apolipoprotein E, an
essential component of lipoproteins, plays an important role
in bone metabolism by facilitating vitamin K-dependent
carboxylation of bone proteins. In the general population,
apolipoprotein e4, a gene that encodes for apolipoprotein E, is
a risk factor for coronary artery disease, Alzheimer’s disease,
low BMD, and increased fracture risk.27–30 To our knowledge, there are no previously published data that correlated
serum apolipoprotein E with risk of bone loss in the HIVinfected population. Further studies are needed to explore
whether this biomarker is also linked with several inflammatory diseases, including Alzheimer’s disease and atherosclerosis, among HIV-infected persons.
Similar to other studies, we found that the majority of our
participants on at least 2 years of cART had stable BMD
over time.8 However, we identified an increasing proportion
of participants with ‡5% BMD decline over 4 years, though
without a change in proportions of WHO-defined osteopenia/
osteoporosis. The magnitude of bone loss in these relatively

young individuals is compelling and is similar to that associated with a year of corticosteroid treatment and greater
than that seen among HIV-uninfected perimenopausal or
postmenopausal women and older men.31–34 Among these
participants, bone loss was more common among female
subjects, current smokers, and those with longer stavudine
use. Unfortunately, the smaller sample size of this longitudinal cohort limited statistical power. Nonetheless, this
trend is not surprising since female sex and tobacco use are
traditional risk factors for osteoporosis and stavudine use
has been associated with bone loss in several clinical trials.35,36 Further studies with long-term follow-up and larger
numbers of participants are needed to investigate whether
this degree of bone loss will lead to osteopenia and osteoporosis over time.
Baseline BMD influences the rate of bone loss among
premenopausal and postmenopausal women in the general
population.37 Studies conducted among HIV-infected women
show varying results.6 We found a significant, albeit modest,
correlation between lower baseline BMD and subsequent
gain in BMD at the total hip, with baseline total hip BMD
accounting for only 3.6% of the variance in the total hip BMD
change over time. We may be limited by the fact that our
baseline DXA scans do not reflect a true baseline for the
participants, as the median time since HIV diagnosis was 4.8
years and all had at least 2 years of suppressive cART exposure at time of first DXA scan.

Table 2. Multivariate Logistic Regression Analysis of Factors Associated with Osteoporosis
at Any Anatomical Site, at Baseline, in the SUN Study (n = 653), 2004–2012
Univariate analysis
Characteristic
Age >46 yearsa
Male gender
Nonwhite race
BMI <22.8 kg/m2b
SAT <302.4 kga
Any exercise
Resistance training
Aerobic activity
Unemployed or retired
Current smoking
Alcohol use in last 30 days
Time since HIV diagnosis >8.1 yearsa
Nadir CD4+ <89 c/mm3b
Baseline CD4+ count <323 c/mm3b
Ever used stavudine
Time on tenofovir >1 yearc
Hepatitis C antibody-reactive
Adiponectin >8,025 lg/mld
Leptin <2.2 ng/mlb
25-Hydroxyvitamin D <10 ng/mle
Apolipoprotein E <4.8 mg/literb
Apolipoprotein A1
> 180 mg/dl for men, 205 mg/dl for women
a

Odds ratio (95% CI)

Multivariate analysis

p value

Odds ratio (95% CI)

(1.40–4.06)
(0.89–3.84)
(1.23–3.51)
(2.33–6.86)
(1.54–9.97)
(0.34–0.99)
(0.40–1.22)
(0.31–0.94)
(1.60–4.78)
(1.03–2.97)
(0.56–1.74)
(0.27–0.81)
(1.10–3.30)
(1.26–3.73)
(1.00–2.96)
(1.23–3.63)
(1.44–5.23)
(0.30–0.89)
(1.03–3.09)
(1.19–4.98)
(1.03–3.00)

0.001
0.099
0.007
< 0.001
0.004
0.048
0.210
0.031
< 0.001
0.038
0.966
0.006
0.022
0.006
0.052
0.007
0.002
0.018
0.038
0.015
0.038

2.27 (1.26–4.07)

0.006

2.58 (1.45–4.65)
3.96 (2.23–7.07)

0.001
< 0.001

2.16 (1.16–3.94)

0.013

2.47 (1.35–4.48)

0.003

1.97 (1.10–3.59)

0.023

2.75 (1.14–6.64)

0.025

2.39
1.85
2.07
3.99
3.92
0.58
0.70
0.54
2.76
1.75
0.99
0.47
1.90
2.16
1.72
2.12
2.75
0.52
1.79
2.43
1.76

p value

Upper quartile.
Lower quartile.
Cut off decided by investigators.
d
Median.
e
Definition of severe vitamin D deficiency.
SUN Study, Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy; CI, confidence interval; BMI,
body mass index; SAT, subcutaneous adipose tissue.
b
c
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FIG. 1. Comparison of femoral neck bone mineral density
(BMD) between HIV-infected Study to Understand the
Natural History of HIV and AIDS in the Era of Effective
Therapy (SUN) study participants and matched controls
from the National Health and Nutrition Examination Survey
(NHANES) (n = 462), 2004–2012. The distribution of femoral neck BMD (as measured by calculated T-scores) for 462
HIV-infected individuals from the SUN (solid line) and 462
control subjects matched for age, sex, race, and body mass
index is demonstrated. The data for both groups are normally
distributed but demonstrate a significant decrement in BMD
among the HIV-infected cohort compared to the NHANES
cohort (mean T-score -0.81 vs. -0.33, p < 0.001).
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The high prevalence of osteopenia and osteoporosis in our
cohort and the identification of an increasing proportion of
participants who continued to experience substantial bone
loss over four years can better be contextualized by the increased fracture risk associated with low BMD. Higher
fractures rates have been consistently reported among HIVinfected persons compared to the general population.38,39
Moreover, HIV-infected persons often have risk factors for
falling, such as multimorbidity, polypharmacy, peripheral
neuropathy, and frailty, which lead to the development of
fragility fracture at much younger ages.39–41
Our study was subject to several limitations. The SUN
Study was conducted in only four U.S. cities; therefore, data
presented here may not be generalizable to all HIV-infected
persons in care in the United States. Our cohort is also heterogeneous with regard to antiretroviral exposure and other
risk factors for low BMD. We also did not match subjects
in the NHANES for tobacco use. As noted previously, our
longitudinal analysis was limited by the small number of
subjects and the short duration of follow-up that reduced
statistical power. Furthermore, we did not have longitudinal
data regarding participants’ use of vitamin D, calcium supplements, bisphosphonates, or corticosteroids.
In conclusion, we found a high prevalence of osteopenia
and osteoporosis among a cohort of HIV-infected persons that
was significantly higher than that among matched controls
from NHANES. Additionally, we found novel associations
between baseline osteoporosis and low serum apolipoprotein
E and being unemployed or retired. We also identified an
increasing proportion of participants who continued to have a
substantial degree of bone loss over 4 years, suggesting the

FIG. 2. Proportion of participants with at least 5% loss in bone mineral density over 4 years of follow-up (n = 170), the
Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN) Study 2004–2012. The
increasing proportion of participants in the SUN Study with ‡5% decline in bone mineral density (BMD) at key sites for
osteoporotic fractures (femoral neck, total hip, and lumbar spine) as measured by annual dual X-ray absorptiometry (DXA)
scan is demonstrated. Data are also included from 170 persons who maintained virologic suppression for ‡2 years on
antiretroviral therapy prior to the baseline DXA. At the 4-year DXA scan, ‡5% loss of BMD was identified in 15% of
subjects at the femoral neck, 15% at the total hip, and 17% at the lumbar spine. The proportion of subjects with ‡5% decline
in BMD at any of these sites is also demonstrated, showing that by 4 years, 31% of all persons had experienced ‡5% BMD
decline at one or more relevant sites.
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need for monitoring and potential clinical interventions.
Further studies are warranted to determine effective measures
to prevent fragility fractures as our population ages.

ESCOTA ET AL.
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